查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1776694

2032 年 CRISPR 基因编辑市场预测：按产品类型、技术、应用、最终用户和地区进行的全球分析

CRISPR Gene Editing Market Forecasts to 2032 - Global Analysis By Product Type, Technology (CRISPR/Cas9, Base Editing, CRISPR/Cpf1, Prime Editing and Other Technologies), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球 CRISPR 基因编辑市场预计在 2025 年达到 23 亿美元，到 2032 年将达到 128.2 亿美元，预测期内的复合年增长率为 27.8%。

CRISPR基因编辑是一种尖端生物技术工具，它使研究人员能够精确地修改生物体的DNA。受细菌防御机制的启发，CRISPR（成簇规律间隔短回文重复序列）使用一种名为Cas9的蛋白质，在可自订RNA序列的引导下，在特定位点切割DNA。这使得研究人员能够精确地添加、删除或替换遗传物质。此外，CRISPR彻底改变了基因研究，并在生物技术、医学和农业领域拥有巨大的潜力。 CRISPR为开发新型治疗方法、改良作物性状和治疗遗传疾病提供了令人兴奋的可能性。

在欧洲，英国国家医疗服务体系（NHS）核准了Casgevy基因疗法用于治疗输血依赖性β-地中海贫血，这是欧洲首个由政府支持的CRISPR临床应用。该治疗方法初步估计每位患者费用约为165万英镑，将透过NHS惠及最多460名合格的患者，标誌着CRISPR治疗方法在欧洲临床应用方面具有历史性里程碑。

遗传疾病的兴起

CRISPR 基因编辑市场很大程度上受到全球镰状细胞性贫血、β-地中海贫血、亨廷顿舞蹈症和囊肿纤维化等遗传疾病日益流行的推动。这些疾病的传统治疗选择稀少、昂贵，且往往只针对症状，而无法解决背后的遗传原因。 CRISPR 可直接编辑缺陷基因，从而有可能治疗方法。随着人们认识的提高和诊断能力的提高，人们能够更早发现更多患者，从而推动了对治癒性疗法的需求。此外，英国核准，正在推动 CRISPR 从实验用途走向实际治疗用途。

社会和道德问题

围绕着 CRISPR 基因编辑（尤其是生殖细胞系编辑和人类胚胎的使用）的伦理争议，是该技术市场发展的最大障碍之一。人们对「设计婴儿」、意外后果以及人类基因组被改变并可能遗传给后代对社会产生的长期影响存在严重担忧。宗教、文化和哲学信念进一步加剧了公众的接受度，尤其是在基因编辑被用于智力或外貌等非治疗性增强提案时。此外，人类生殖细胞系编辑仍受到许多监管机构的禁止或严格限制。

成为无法治癒的罕见疾病

CRISPR 为治疗数千种目前尚无治疗方法的罕见遗传疾病提供了突破性的机会。 CRISPR 有可能在分子层面上纠正导致戴-萨克斯病、Duchenne氏肌肉失养症和莱伯氏先天性黑朦症等疾病的特定基因突变。由于患者人数较少，传统的罕见疾病药物研发往往在经济上难以承受，而 CRISPR 的精准性使其能够实现有针对性的、可扩展的治疗方法。此外，政府和监管机构正在利用孤儿药资格认定、优先审查和津贴来鼓励对罕见疾病的研究。

正在进行的知识产权纠纷

CRISPR基因编辑市场正捲入一场旷日持久的专利纠纷，主要机构包括加州大学柏克莱分校和布罗德研究所。由于这些围绕基本专利的法律纠纷，谁有权使用和销售CRISPR-Cas9技术的各个部分已成为一个高度不确定的问题。对于寻求开发基于CRISPR产品的公司来说，许可证是一项必要的程序，它复杂、成本高昂，并且因司法管辖区而异。如果没有明确的营运自由定义，它将阻碍新兴企业，扼杀创新，并可能导致法律诉讼。此外，模糊的智慧财产权格局会阻碍合作，增加成本，并吓跑潜在的投资者。

COVID-19的影响：

COVID-19 疫情对 CRISPR 基因编辑市场产生了双重影响。一方面，由于供应链中断、临床试验延迟以及研究资金重新分配，治疗性 CRISPR 应用的进展暂时搁置。实验室容量减少和关闭也推迟了许多与 COVID-19 无关的基因编辑倡议。然而，疫情也推动了基于 CRISPR 的诊断技术快速发展，SHERLOCK 和 DETECTR 等工具被重新用于快速且准确地检测 SARS-CoV-2。除了提高公众认知度和投资者信心之外，这种即时应用还证明了 CRISPR 在基因组编辑之外的适用性。

预计 CRISPR/Cas9 细分市场在预测期内将占据最大份额

由于易用性、高效性和价格实惠，CRISPR/Cas9 细分市场预计将在预测期内占据最大市场占有率。 CRISPR/Cas9 是第一个也是最受欢迎的 CRISPR 系统，它彻底改变了基因组编辑。它利用嚮导 RNA 和 Cas9 酶在特定 DNA 位置製造双链，从而实现标靶基因修饰。由于其在学术研究、药物开发和农业生物技术领域的广泛应用，CRISPR/Cas9 已成为现代基因编辑的基石。此外，CRISPR/Cas9 目前已在许多临床试验中用于治疗感染疾病、癌症和遗传疾病，进一步巩固了其在全球 CRISPR 市场的主导地位。

预计製药和生物製药领域在预测期内将以最高的复合年增长率成长

预计製药和生物製药公司细分市场将在预测期内实现最高成长率。基因疗法开发投资的不断增加、个人化医疗的需求以及基于 CRISPR 的药物研发管线的加速发展是这项扩张的关键驱动力。为了开发感染疾病、罕见遗传疾病和癌症的治疗方法，这些公司正在积极采用 CRISPR 技术。与生物技术公司和 CRISPR 先驱的合作正在加速临床试验和监管核准。此外，随着 Casjevy 等 CRISPR 疗法核准，製药公司正在加强生产和商业化力度，确保该市场作为成长最快的基因编辑市场占据主导地位。

比最大的地区

预计北美将在预测期内占据最大的市场占有率，这主要得益于其率先采用尖端基因编辑技术、强大的生物技术基础设施以及充足的研究资金。美国处于领先地位，其关键产业相关人员和学术机构高度集中，监管支持有力，并进行了大量的CRISPR相关临床试验。在生技公司积极推动治疗方案开发的同时，美国国立卫生研究院（NIH）等政府机构也大力投资基因组编辑研究。该地区还受益于强大的智慧财产权框架和高度的公私合作。

复合年增长率最高的地区：

预计亚太地区将在预测期内呈现最高的复合年增长率，这得益于政府支持、精准医疗投资以及生物技术研究的成长。中国、日本、韩国和印度等国家正在基因组学领域取得快速发展，基于 CRISPR 的研究计划和临床研究不断增加。旨在促进生物技术创新的资助计划和监管变化进一步推动了市场扩张。此外，由于人口众多、遗传疾病发病率不断上升以及国际製药公司对本地合作的兴趣日益浓厚，亚太地区正成为 CRISPR 技术应用的主要新兴中心。

免费客製化服务：

此报告的订阅者可以从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球 CRISPR 基因编辑市场（依产品类型）

  • CRISPR套件和试剂
    • 套件和酶
    • 图书馆
    • 设计工具
    • 抗体
    • 其他 CRISPR套件和试剂
  • CRISPR服务
    • gRNA设计与载体构建
    • 细胞株工程
    • 筛检服务
    • 其他 CRISPR 服务

6. 全球 CRISPR 基因编辑市场（按技术）

  • CRISPR/Cas9
  • 碱基编辑
  • CRISPR/Cpf1（Cas12a）
  • Prime Edit
  • 其他技术

7. 全球 CRISPR 基因编辑市场（按应用）

  • 农业
    • 改善作物特性
    • 牲畜基因组编辑
    • 病原体抗性
  • 生物医学
    • 治疗性基因组编辑
    • 疾病模型
    • 功能基因体学
    • 基因治疗研究
  • 工业生物技术
    • 微生物菌株工程
    • 生质燃料生产
    • 酵素优化
  • 其他用途

8. 全球 CRISPR 基因编辑市场（按最终用户）

  • 学术机构与研究中心
  • 生技公司
  • 合约研究组织（CRO）
  • 製药和生物製药公司
  • 其他最终用户

9. 全球 CRISPR 基因编辑市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：主要发展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Danaher
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Bio-Rad Laboratories Inc
  • GenScript Inc
  • Agilent Technologies, Inc.
  • New England Biolabs, Inc.
  • CRISPR Therapeutics AG
  • OriGene Technologies, Inc.
  • Synthego Corporation
  • Cellecta, Inc.
  • Rockland Immunochemicals, Inc.
  • Integrated DNA Technologies, Inc.
  • Beam Therapeutics Inc
  • Locus Biosciences Inc
Product Code: SMRC30025

According to Stratistics MRC, the Global CRISPR Gene Editing Market is accounted for $2.30 billion in 2025 and is expected to reach $12.82 billion by 2032 growing at a CAGR of 27.8% during the forecast period. CRISPR gene editing is a cutting-edge biotechnology tool that enables researchers to precisely modify living things' DNA. Drawing inspiration from a bacterial defense mechanism, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) employs a protein called Cas9 to cut DNA at specific sites under the guidance of an RNA sequence that can be customized. This gives researchers the ability to precisely add, remove, or replace genetic material. Moreover, CRISPR has revolutionized genetic research and has enormous potential in biotechnology, medicine, and agriculture. It presents exciting opportunities for the development of novel treatments, the improvement of crop traits, and the treatment of genetic disorders.

According to the first government-backed clinical application of CRISPR in Europe, NHS England has approved the use of the gene therapy Casgevy for transfusion-dependent beta-thalassemia. The treatment-initially listed at approximately £1.65 million per patient-is being offered through the NHS to up to 460 eligible patients, marking a historic milestone in the clinical adoption of CRISPR-based therapies across Europe.

Market Dynamics:

Driver:

Growing incidence of genetic conditions

The CRISPR gene editing market is being driven largely by the increasing prevalence of genetic diseases like sickle cell anemia, beta-thalassemia, Huntington's disease, and cystic fibrosis worldwide. In contrast to addressing the underlying genetic causes, traditional treatment options for these conditions are frequently scarce, costly, and symptom-focused. CRISPR directly edits faulty genes, potentially providing a remedy. The need for curative therapies is being fueled by the increased early identification of more patients due to increased awareness and improved diagnostic capabilities. Additionally, with regulatory approvals such as the UK NHS's and FDA's approval of Casgevy, CRISPR is progressing from the experimental stage to practical therapeutic use.

Restraint:

Social and ethical issues

The ethical controversy surrounding the use of CRISPR gene editing, especially in germline editing and human embryos, is one of the biggest obstacles to the market. There are serious worries about "designer babies," unforeseen consequences, and the long-term effects on society when the human genome is altered in ways that can be passed on to future generations. Public acceptance is further complicated by religious, cultural, and philosophical beliefs, particularly when editing is suggested for non-therapeutic enhancements like intelligence or appearance. Furthermore, human germline editing is still prohibited or severely restricted by numerous regulatory bodies.

Opportunity:

Growth into untreatable and rare illnesses

CRISPR presents a game-changing chance to treat thousands of uncommon genetic illnesses for which there is currently no cure. CRISPR may be able to fix certain gene mutations that cause diseases like Tay-Sachs, Duchenne muscular dystrophy, and Leber congenital amaurosis at the molecular level. Small patient populations often make traditional drug development for rare diseases financially unfeasible, but CRISPR's accuracy enables targeted, scalable therapeutic approaches. Additionally, orphan drug designations, priority reviews, and grant funding are being used by governments and regulatory bodies to encourage research into rare diseases.

Threat:

Continuous intellectual property (IP) conflicts

The market for CRISPR gene editing is enmeshed in protracted patent disputes between leading organizations, including the University of California, Berkeley, and the Broad Institute. Who has the authority to use and market different parts of the CRISPR-Cas9 technology is a matter of considerable uncertainty as a result of these legal disputes over the fundamental patents. Licenses are necessary for businesses wishing to create CRISPR-based products, and they can be complicated, costly, and jurisdiction-specific. Without a clear definition of freedom to operate, this could discourage startups, impede innovation, or lead to legal action. Additionally, the ambiguous IP landscape hinders cooperation, raises expenses, and deters potential investors.

Covid-19 Impact:

The COVID-19 pandemic affected the market for CRISPR gene editing in two ways: it brought opportunities and challenges. On the one hand, advancements in therapeutic CRISPR applications were momentarily put on hold due to supply chain disruptions, clinical trial delays, and reallocated research funds. Due to lab capacity reductions and lockdowns, numerous gene-editing initiatives unrelated to COVID-19 experienced delays. However, CRISPR-based diagnostics have advanced rapidly as a result of the pandemic, with tools like SHERLOCK and DETECTR being repurposed for the quick and precise detection of SARS-CoV-2. In addition to increasing public awareness and investor confidence, this real-time application demonstrated CRISPR's adaptability beyond genome editing.

The CRISPR/Cas9 segment is expected to be the largest during the forecast period

The CRISPR/Cas9 segment is expected to account for the largest market share during the forecast period because of its ease of use, effectiveness, and affordability, CRISPR/Cas9, the first and most popular CRISPR system, has completely changed genome editing. It enables targeted gene modifications by causing double-strand breaks at particular DNA locations using a guide RNA and the Cas9 enzyme. It is the cornerstone of contemporary gene editing due to its widespread application in scholarly research, pharmaceutical development, and agricultural biotechnology. Moreover, CRISPR/Cas9 is currently being used in a large number of clinical trials to treat infectious diseases, cancer, and genetic disorders, further solidifying its leading position in the global CRISPR market.

The pharmaceutical and biopharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical and biopharmaceutical companies segment is predicted to witness the highest growth rate. Growing investments in the development of gene therapies, the need for personalized medicine, and the quickening of CRISPR-based drug pipelines are the main drivers of this expansion. To create treatments for infectious diseases, rare genetic diseases, and cancer, these businesses are aggressively incorporating CRISPR technologies. Partnerships with biotech companies and CRISPR pioneers have accelerated clinical trials and regulatory approvals. Additionally, pharmaceutical companies are increasing production and commercialization of CRISPR therapies, such as Casgevy, as they receive approval, securing this market's dominance as the fastest-growing gene editing market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, mainly because of its early adoption of cutting-edge gene-editing technologies, strong biotechnology infrastructure, and generous research funding. With a concentration of important industry players and academic institutions, favorable regulatory support, and extensive clinical trials related to CRISPR, the United States leads the way. While biotech companies actively seek therapeutic development, government organizations such as the NIH make significant investments in genome-editing research. Furthermore, the area also gains from a robust intellectual property framework and a high degree of public-private cooperation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by growing government assistance, precision medicine investments, and biotechnology research. With an increasing number of CRISPR-based research projects and clinical studies, nations like China, Japan, South Korea, and India are making rapid strides in genomics. Market expansion is further supported by funding initiatives and regulatory changes meant to promote biotech innovation. Moreover, Asia-Pacific is positioned as a major emerging hub for the adoption of CRISPR technology due to its large population base, rising prevalence of genetic disorders, and growing interest from international pharmaceutical companies in local partnerships.

Key players in the market

Some of the key players in CRISPR Gene Editing Market include Danaher, Thermo Fisher Scientific, Inc., Merck KGaA, Bio-Rad Laboratories Inc, GenScript Inc, Agilent Technologies, Inc., New England Biolabs, Inc., CRISPR Therapeutics AG, OriGene Technologies, Inc., Synthego Corporation, Cellecta, Inc., Rockland Immunochemicals, Inc., Integrated DNA Technologies, Inc., Beam Therapeutics Inc and Locus Biosciences Inc.

Key Developments:

In June 2025, Thermo Fisher Scientific announced that it has been awarded a five-year, $94.5 million contract by the U.S. Department of Defense (DoD) to supply the Navy with a next-generation dosimetry system alongside updated radiation health and database management software. The U.S. Navy operates the world's most technologically advanced naval fleet and is the largest defense user of dosimetry systems globally.

In April 2025, Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics, for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents. The deal came at a price tag about 20% lower than what analysts expected due to lack of other serious bidders and the overall devaluation of the U.S. biotech sector. CEO Belen Garijo said the challenges emerging in the United States were reflected in the final bid price.

In January 2025, Danaher Corporation announced that it has signed a definitive agreement to sell its Pacific Scientific Aerospace business to Meggitt PLC, a global aerospace and defense company. Danaher simultaneously received a binding offer from Meggitt to acquire the Artus business which remains open for 12 months. As required by French law, Danaher must consult with the Artus works council prior to concluding an agreement for the sale of the Artus business.

Product Types Covered:

  • CRISPR Kits & Reagent
  • CRISPR Services

Technologies Covered:

  • CRISPR/Cas9
  • Base Editing
  • CRISPR/Cpf1 (Cas12a)
  • Prime Editing
  • Other Technologies

Applications Covered:

  • Agricultural
  • Biomedical
  • Industrial Biotechnology
  • Other Applications

End Users Covered:

  • Academic Institutes and Research Centres
  • Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Pharmaceutical and Biopharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global CRISPR Gene Editing Market, By Product Type

  • 5.1 Introduction
  • 5.2 CRISPR Kits & Reagent
    • 5.2.1 Kits and Enzymes
    • 5.2.2 Libraries
    • 5.2.3 Design Tools
    • 5.2.4 Antibodies
    • 5.2.5 Other CRISPR Kits & Reagents
  • 5.3 CRISPR Services
    • 5.3.1 gRNA Design and Vector Construction
    • 5.3.2 Cell Line Engineering
    • 5.3.3 Screening Services
    • 5.3.4 Other CRISPR Services

6 Global CRISPR Gene Editing Market, By Technology

  • 6.1 Introduction
  • 6.2 CRISPR/Cas9
  • 6.3 Base Editing
  • 6.4 CRISPR/Cpf1 (Cas12a)
  • 6.5 Prime Editing
  • 6.6 Other Technologies

7 Global CRISPR Gene Editing Market, By Application

  • 7.1 Introduction
  • 7.2 Agricultural
    • 7.2.1 Crop Trait Improvement
    • 7.2.2 Livestock Genome Editing
    • 7.2.3 Pathogen Resistance
  • 7.3 Biomedical
    • 7.3.1 Therapeutic Genome Editing
    • 7.3.2 Disease Models
    • 7.3.3 Functional Genomics
    • 7.3.4 Gene Therapy Research
  • 7.4 Industrial Biotechnology
    • 7.4.1 Microbial Strain Engineering
    • 7.4.2 Biofuel Production
    • 7.4.3 Enzyme Optimization
  • 7.5 Other Applications

8 Global CRISPR Gene Editing Market, By End User

  • 8.1 Introduction
  • 8.2 Academic Institutes and Research Centres
  • 8.3 Biotechnology Companies
  • 8.4 Contract Research Organizations (CROs)
  • 8.5 Pharmaceutical and Biopharmaceutical Companies
  • 8.6 Other End Users

9 Global CRISPR Gene Editing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Danaher
  • 11.2 Thermo Fisher Scientific, Inc.
  • 11.3 Merck KGaA
  • 11.4 Bio-Rad Laboratories Inc
  • 11.5 GenScript Inc
  • 11.6 Agilent Technologies, Inc.
  • 11.7 New England Biolabs, Inc.
  • 11.8 CRISPR Therapeutics AG
  • 11.9 OriGene Technologies, Inc.
  • 11.10 Synthego Corporation
  • 11.11 Cellecta, Inc.
  • 11.12 Rockland Immunochemicals, Inc.
  • 11.13 Integrated DNA Technologies, Inc.
  • 11.14 Beam Therapeutics Inc
  • 11.15 Locus Biosciences Inc

List of Tables

  • Table 1 Global CRISPR Gene Editing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global CRISPR Gene Editing Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global CRISPR Gene Editing Market Outlook, By CRISPR Kits & Reagent (2024-2032) ($MN)
  • Table 4 Global CRISPR Gene Editing Market Outlook, By Kits and Enzymes (2024-2032) ($MN)
  • Table 5 Global CRISPR Gene Editing Market Outlook, By Libraries (2024-2032) ($MN)
  • Table 6 Global CRISPR Gene Editing Market Outlook, By Design Tools (2024-2032) ($MN)
  • Table 7 Global CRISPR Gene Editing Market Outlook, By Antibodies (2024-2032) ($MN)
  • Table 8 Global CRISPR Gene Editing Market Outlook, By Other CRISPR Kits & Reagents (2024-2032) ($MN)
  • Table 9 Global CRISPR Gene Editing Market Outlook, By CRISPR Services (2024-2032) ($MN)
  • Table 10 Global CRISPR Gene Editing Market Outlook, By gRNA Design and Vector Construction (2024-2032) ($MN)
  • Table 11 Global CRISPR Gene Editing Market Outlook, By Cell Line Engineering (2024-2032) ($MN)
  • Table 12 Global CRISPR Gene Editing Market Outlook, By Screening Services (2024-2032) ($MN)
  • Table 13 Global CRISPR Gene Editing Market Outlook, By Other CRISPR Services (2024-2032) ($MN)
  • Table 14 Global CRISPR Gene Editing Market Outlook, By Technology (2024-2032) ($MN)
  • Table 15 Global CRISPR Gene Editing Market Outlook, By CRISPR/Cas9 (2024-2032) ($MN)
  • Table 16 Global CRISPR Gene Editing Market Outlook, By Base Editing (2024-2032) ($MN)
  • Table 17 Global CRISPR Gene Editing Market Outlook, By CRISPR/Cpf1 (Cas12a) (2024-2032) ($MN)
  • Table 18 Global CRISPR Gene Editing Market Outlook, By Prime Editing (2024-2032) ($MN)
  • Table 19 Global CRISPR Gene Editing Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 20 Global CRISPR Gene Editing Market Outlook, By Application (2024-2032) ($MN)
  • Table 21 Global CRISPR Gene Editing Market Outlook, By Agricultural (2024-2032) ($MN)
  • Table 22 Global CRISPR Gene Editing Market Outlook, By Crop Trait Improvement (2024-2032) ($MN)
  • Table 23 Global CRISPR Gene Editing Market Outlook, By Livestock Genome Editing (2024-2032) ($MN)
  • Table 24 Global CRISPR Gene Editing Market Outlook, By Pathogen Resistance (2024-2032) ($MN)
  • Table 25 Global CRISPR Gene Editing Market Outlook, By Biomedical (2024-2032) ($MN)
  • Table 26 Global CRISPR Gene Editing Market Outlook, By Therapeutic Genome Editing (2024-2032) ($MN)
  • Table 27 Global CRISPR Gene Editing Market Outlook, By Disease Models (2024-2032) ($MN)
  • Table 28 Global CRISPR Gene Editing Market Outlook, By Functional Genomics (2024-2032) ($MN)
  • Table 29 Global CRISPR Gene Editing Market Outlook, By Gene Therapy Research (2024-2032) ($MN)
  • Table 30 Global CRISPR Gene Editing Market Outlook, By Industrial Biotechnology (2024-2032) ($MN)
  • Table 31 Global CRISPR Gene Editing Market Outlook, By Microbial Strain Engineering (2024-2032) ($MN)
  • Table 32 Global CRISPR Gene Editing Market Outlook, By Biofuel Production (2024-2032) ($MN)
  • Table 33 Global CRISPR Gene Editing Market Outlook, By Enzyme Optimization (2024-2032) ($MN)
  • Table 34 Global CRISPR Gene Editing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 35 Global CRISPR Gene Editing Market Outlook, By End User (2024-2032) ($MN)
  • Table 36 Global CRISPR Gene Editing Market Outlook, By Academic Institutes and Research Centres (2024-2032) ($MN)
  • Table 37 Global CRISPR Gene Editing Market Outlook, By Biotechnology Companies (2024-2032) ($MN)
  • Table 38 Global CRISPR Gene Editing Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
  • Table 39 Global CRISPR Gene Editing Market Outlook, By Pharmaceutical and Biopharmaceutical Companies (2024-2032) ($MN)
  • Table 40 Global CRISPR Gene Editing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.